Literature DB >> 7643486

Metastatic orbital tumors.

I Günalp1, K Gündüz.   

Abstract

A review was made of the clinical data of 28 patients with metastatic orbital disease diagnosed in our clinic between 1972 and 1993. Fifteen were men and 13 were women. The average age at diagnosis was 58.7 years. The right orbit was involved in 12 and the left orbit in 14 cases. Two cases had bilateral orbital involvement. Breast carcinoma was the most frequent tumor (8 of 28, 28.6%) followed by neuroblastoma (7 of 28, 25.0%), lung carcinoma (6 of 28, 21.4%), prostate carcinoma (3 of 28, 10.7%), gastrointestinal carcinoma (2 of 28, 7.1%), renal cell carcinoma and thyroid carcinoma (1 of 28, 3.6% each). Proptosis (67.9%), motility disturbance (57.1%) and mass (50.0%) were the three most common presenting signs. Enophthalmos was noted in two cases with breast carcinoma. Nine cases presented with ophthalmic signs and metastatic tumor was recognized later. In the remaining 19 cases, the diagnosis of the primary tumor preceded the onset of orbital metastasis. The time interval between the detection of the primary malignancy and metastatic orbital tumor was shortest for lung carcinoma (mean: 2 months) and longest for breast carcinoma (mean: 34 months). Radiotherapy and chemotherapy were applied in 12 cases. Improvement in orbital signs and visual acuity was noted in 5 cases. Radiotherapy, chemotherapy and hormonal therapy were used in 8 patients and improvement in orbital signs was noted in 4 of these patients. Four of 28 patients (2 with breast carcinomas, one with prostate carcinoma and one with thyroid carcinoma) survived longer than 5 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7643486

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  11 in total

Review 1.  [Orbit : Part 2: Diseases of the globe and retrobulbar space].

Authors:  W Reith; R Mühl-Benninghaus
Journal:  Radiologe       Date:  2017-06       Impact factor: 0.635

2.  Orbital mass as first presentation of metastatic p16-positive oropharyngeal squamous cell carcinoma.

Authors:  J Corbett; D Wilke; J Trites; N Lamond
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

3.  [Orbital metastases of breast cancer. Radiologic features].

Authors:  F Akda; F Hafezi; H A G Heule-Dieleman; W A van den Bosch; G P M Luyten; H L J Tanghe; D Paridaens
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

4.  Metastatic orbital tumors in southern China during an 18-year period.

Authors:  Jianhua Yan; Shaohui Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-06       Impact factor: 3.117

5.  Issues raised by a case of orbital metastatic disease.

Authors:  S Beatty; I Ntountas; A Tyagi; R N Downes; G R Kirkby
Journal:  Orbit       Date:  2009-07-08

6.  Orbital Metastasis of Multiple Myeloma: Case Report.

Authors:  Mustafa Vatansever; Fatma Merve Bozkurt; Erdem Dinç; Eda Bengi Yılmaz; Erdinç Nayir; Ayşe Ayça Sarı; Özlem Yıldırım; Tuba Kara
Journal:  Turk J Ophthalmol       Date:  2016-06-06

Review 7.  Orbital Metastases: When to Suspect? When to biopsy?

Authors:  Richard Cutler Allen
Journal:  Middle East Afr J Ophthalmol       Date:  2018 Apr-Jun

8.  Breast Carcinoma Metastasis to the Medial Rectus Muscle: Case Report

Authors:  Özge Yabaş Kızıloğlu; Fatma Paksoy Türköz; Özgün Melike Totuk Gedar; Mert Mestanoğlu; Özlem Yapıcıer
Journal:  Turk J Ophthalmol       Date:  2019-06-27

9.  A clinical update and radiologic review of pediatric orbital and ocular tumors.

Authors:  Ajay A Rao; John H Naheedy; James Y-Y Chen; Shira L Robbins; Hema L Ramkumar
Journal:  J Oncol       Date:  2013-03-12       Impact factor: 4.375

10.  Second primary malignancies of eye and ocular adnexa after a first primary elsewhere in the body.

Authors:  Ahmad Samir Alfaar; Anas M Saad; Mahmoud Tawfik KhalafAllah; Omneya Ezzat Elsherif; Moataz Hamed Osman; Olaf Strauß
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-09-01       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.